Valgu sünteesimiseks kasutatavate aminohapete lisandid
Toote detail
| NO | Tooted | Cas nr | Peamine kvaliteedinäitaja | |||
| Puhtus | Max. lisand | Lahusti kogujääk | Niiskus | |||
| 1 | FMOC-β-Ala-Ala-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 2 | Fmoc-d-ala-d-ala-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 3 | FMOC-β-Ala-D-Ala-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 4 | Fmoc-arg (pbf) -arg (pbf) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 5 | FMOC-β-Ala-ARG (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 6 | Fmoc-d-arg (pbf) -d-arg (pbf) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 7 | Fmoc-β-ala-d-arg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 8 | Fmoc-homoarg (PBF) -homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 9 | Fmoc-β-ala-homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 10 | Fmoc-asn (trt) -asn (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 11 | Fmoc-β-ala-asn (trt) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 12 | Fmoc-asp (otbu) -asp (otbu) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 13 | FMOC-β-Ala-ASP (OTBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 14 | Fmoc-cys (trt) -cys (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 15 | FMOC-β-Ala-Cys (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 16 | FMOC-CYS (ACM) -CYS (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 17 | FMOC-β-Ala-Cys (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 18 | Fmoc-gln (trt) -gln (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 19 | FMOC-β-Ala-GLN (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 20 | Fmoc-glu (otbu)-glu (otbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 21 | Fmoc-β-ala-glu (otbu) -oh.h2o | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 22 | FMOC-β-Ala-Gly-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 23 | Fmoc-his (trt) -his (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 24 | FMOC-β-Ala (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 26 | Fmoc-β-ala-ile-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 28 | Fmoc-β-ala-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 29 | FMOC-D-LEU-D-LEU-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 30 | Fmoc-β-ala-d-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 31 | FMOC-LYS (BOC) -LYS (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 32 | FMOC-β-Ala-Lys (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 33 | Fmoc-lys (alloc) -lys (alloc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 34 | FMOC-β-Ala-Lys (alloc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 35 | FMOC-MET-MET-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 36 | FMOC-β-Ala-Met-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 37 | Fmoc-orn (boc) -n (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 38 | Fmoc-β-alarn (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 39 | Fmoc-phe-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 40 | FMOC-β-Ala-Phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 41 | FMOC-D-Phe-D-Phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 42 | FMOC-β-ala-D-Phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 43 | Fmoc-pro-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 44 | FMOC-β-Ala-Pro-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 45 | FMOC-Ser (TBU) -Ser (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 46 | Fmoc-β-ala-ser (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 47 | FMOC-Ser (TRT) -Ser (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 48 | Fmoc-β-ala-ser (trt) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 49 | Fmoc-thr (tBU) -Thr (tBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 50 | FMOC-β-Ala-Thr (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 51 | Fmoc-trp (boc) -trp (boc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 52 | FMOC-β-Ala-Trp (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 53 | Fmoc-d-trp (boc) -d-trp (boc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 54 | Fmoc-β-ala-d-trp (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 55 | Fmoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 56 | FMOC-β-Ala-Tyr (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 57 | Fmoc-d-tyr (et) -d-tyr (et) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 58 | FMOC-β-Ala-D-Tyr (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 59 | Fmoc-tyr (mina) -tyr (mina) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 60 | FMOC-β-Ala-Tyr (ME) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 61 | FMOC-VAL-VAL-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 62 | FMOC-β-Ala-Val-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 63 | Fmoc-d-cit-d-cit-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 64 | Fmoc-β-ala-d-cit-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 65 | FMOC-β-Ala-Dab-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 66 | Fmoc- (3- (2-naftüül) -d-ala) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 67 | FMOC-β-Ala-3- (2-naftüül) -D-Ala-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 68 | Fmoc- (3- (3-püridinüül) -D-ala) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 69 | FMOC-β-Ala-3- (3-püridinüül) -D-Ala-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 70 | FMOC- (4-kloro-D-Phe) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 71 | Fmoc-β-Ala-4-kloro-D-Phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 73 | Fmoc-β-ala-d-4aph (tbucbm) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 74 | Fmoc-aph (l-hor) -aph (l-hor) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 75 | FMOC-β-Ala-Aph (L-HOR) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 76 | FMOC-LYS (IPR, BOC) -LYS (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 77 | FMOC-β-Ala-Lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 78 | FMOC-β-Ala-AEEA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 79 | Fmoc-aib-aib-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 80 | FMOC-β-Ala-Aib-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 81 | FMOC-ARG-OH | 91000-69-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 82 | H-arg (PBF) -OH | 200115-86-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 83 | FMOC-D-ARG-OH | 130752-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 84 | HD-ARG (PBF) -OH | 200116-81-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 86 | H-homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 88 | Hd-homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 89 | FMOC-ASN-OH | 71989-16-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 90 | H-asn (trt) -oh | 132388-58-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 91 | FMOC-ASP-OH | 119062-05-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 92 | H-ASP (OTBU) -OH | 3057-74-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 93 | FMOC-CYS-OH | 135248-89-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 94 | H-CYS (TRT) -OH | 2799/7/7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 95 | H-CYS (ACM) -OH.HCL | 28798-28-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 97 | H-gln (trt) -oh | 102747-84-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 99 | H-glu (otbu) -oh.h2o | 2419-56-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 100 | FMOC-HIS-OH | 116611-64-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 101 | H-his (trt) -oh | 35146-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 102 | BOC-HIS-OH | 17791-52-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 103 | FMOC-LYS-OH | 105047-45-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 104 | H-lys (boc) -oh | 2418-95-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 105 | H-lys (alloc) -oh | 6298/3/9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 106 | Fmoc-on-oh.hcl | 201046-57-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 107 | H-on (boc) -oh | 13650-49-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 108 | FMOC-Ser-OH | 73724-45-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 109 | H-ser (tbu) -oh | 18822-58-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 110 | H-ser (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 112 | H-thr (tbu) -oh | 4378-13-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 113 | FMOC-Trp-OH | 35737-15-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 114 | H-trp (boc) -oh | 146645-63-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 115 | FMOC-D-Trp-OH | 86123-11-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 119 | FMOC-D-Tyr-OH | 112883-29-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 120 | Hd-tyr (et) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 121 | H-tyr (mina) -oh.hcl | 67423-44-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 122 | Fmoc-d-4aph (CBM) -OH | 324017-22-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 124 | FMOC-LYS (IPR) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 125 | H-lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
Ümber
Hüvitis
Gentolex pakub suurepäraseid tooteid, kui klient tõstab nõutava aja jooksul toote kvaliteeti, kus on piisavalt tõendeid, pakume kompensatsioonide protseduuride käivitamiseks vajalikku analüüsi ja hindamist.
Tootmine
Farmaatsiatoodete mahutavus jõudis tonni klassi, keemiatoodete võime jõu ulatub 100 -st+ klassi, võimalused on hästi varustatud klientide teenindamiseks kogu maailmas.
Teadus- ja arendustegevus
Igal aastal on teadus- ja arendustegevuse meeskond loonud erinevate uute toodete väljatöötamiseks, kui sihtmärgid on seatud, peab iga meeskonna liige jätkama KPI vastutuse ja stiimulipoliitikaga.
